Early onset familial Alzheimer's disease

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase II: 1 Phase IV: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    FLORQUINITAU (18F); HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST N-TERMINALLY TRUNCATED PYROGLUTAMATE-3 AB
    2022-500691-59-00 3 countries n=98
    Ended

Phase IV

1 trial
  • Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V. Academic
    FLORBETABEN (18F); FLUTEMETAMOL (18F)
    2023-503705-10-00 1 country 2024 n=1,126
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase II 0
Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V. Academic 1 Phase IV 1
New trials by year
2024
1
← All indication landscapes